# Useful links

* [FDA, Part 11, Electronic Records; Electronic Signatures - Scope and Application, 2003](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/part-11-electronic-records-electronic-signatures-scope-and-application)
	* [FDA, Guidance for Industry - Electronic Signatures, 2003](https://www.fda.gov/media/75414/download)
	* [FDA, Guidance for Industry - Data Integrity, 2018](https://www.fda.gov/media/119267/download)
	* [FDA, Inspection Guide - Computerized Systems in Drug Establishments, 1983](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-guides/computerized-systems-drug-establishments-283)
* [EMA,  EudraLex, Volume 4 (GMP), Annex 11 - Computerised Systems, 2011)](https://health.ec.europa.eu/system/files/2016-11/annex11_01-2011_en_0.pdf)


* [Pharmaceutical Inspection Convention (PIC/S), Guidance - section 9, 2021](https://www.gmp-compliance.org/files/guidemgr/PI%20041-1.pdf)

* [ECA, _How to handle Legacy Systems if no Audit Trail is available or a "User Login" is not possible?_, 2020](https://www.gmp-compliance.org/gmp-news/how-to-handle-legacy-systems-if-no-audit-trail-is-available-or-a-user-login-is-not-possible)
